A
Andrew Lister
Researcher at Queen Mary University of London
Publications - 46
Citations - 6352
Andrew Lister is an academic researcher from Queen Mary University of London. The author has contributed to research in topics: Follicular lymphoma & Rituximab. The author has an hindex of 23, co-authored 46 publications receiving 5840 citations. Previous affiliations of Andrew Lister include St Bartholomew's Hospital.
Papers
More filters
Journal ArticleDOI
Follicular lymphoma international prognostic index.
Philippe Solal-Celigny,Pascal Roy,Philippe Colombat,J. M. White,James Olen Armitage,Reyes Arranz-Saez,Wing Yan Au,Monica Bellei,Pauline Brice,Dolores Caballero,Bertrand Coiffier,Eulogio Conde-Garcia,Chantal Doyen,Massimo Federico,Richard I. Fisher,Javier García-Conde,Cesare Guglielmi,Anton Hagenbeek,Corinne Haioun,Michael LeBlanc,Andrew Lister,Armando López-Guillermo,Peter McLaughlin,Noel Milpied,Pierre Morel,Nicolas Mounier,Stephen J. Proctor,Ama Z. S. Rohatiner,Paul Smith,Pierre Soubeyran,Hervé Tilly,Umberto Vitolo,Pier Luigi Zinzani,Emanuele Zucca,Emili Montserrat +34 more
TL;DR: The Follicular Lymphoma International Prognostic Index was designed from the data recorded over 8 years of nearly 5000 patients registered worldwide to help provide an optimal treatment option for patients with follicular lymphoma.
Journal ArticleDOI
Rituximab (Anti-CD20 Monoclonal Antibody) for the Treatment of Patients With Relapsing or Refractory Aggressive Lymphoma: A Multicenter Phase II Study
B. Coiffier,Corinne Haioun,Nicolas Ketterer,Andreas Engert,H. Tilly,David D.F. Ma,Peter Johnson,Andrew Lister,M. Feuring Buske,John Radford,R. Capdeville,Volker Diehl,Felix Reyes +12 more
TL;DR: In this first trial of rituximab in DLCL and MCL, patients experienced a significant clinical activity with a low toxicity and should be tested in combination with chemotherapy in such patients.
Journal ArticleDOI
Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
Gilles Salles,John F. Seymour,Fritz Offner,Armando López-Guillermo,David Belada,Luc Xerri,Pierre Feugier,Reda Bouabdallah,John Catalano,Pauline Brice,Dolores Caballero,Corinne Haioun,Lars Moller Pedersen,Alain Delmer,David Simpson,Sirpa Leppä,Pierre Soubeyran,Anton Hagenbeek,Olivier Casasnovas,Tanin Intragumtornchai,Christophe Fermé,Maria Gomes da Silva,Catherine Sebban,Andrew Lister,Jane Estell,Gustavo Milone,Anne Sonet,Myriam Mendila,Bertrand Coiffier,Hervé Tilly +29 more
TL;DR: 2 years of rituximab maintenance therapy after immunochemotherapy as first-line treatment for follicular lymphoma significantly improves PFS.
Journal ArticleDOI
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
John Radford,Timothy M Illidge,Nicholas Counsell,Barry W. Hancock,R. Pettengell,Peter Johnson,Jennie Z Wimperis,Dominic Culligan,Bilyana Popova,Paul Smith,Andrew McMillan,Alison Brownell,Anton Kruger,Andrew Lister,Peter Hoskin,Michael O'Doherty,Sally F. Barrington +16 more
TL;DR: Patients with early-stage Hodgkin's lymphoma and negative PET findings after three cycles of ABVD had a very good prognosis either with or without consolidation radiotherapy, and the noninferiority of the strategy of no further treatment after chemotherapy with regard to progression-free survival did not show.
Journal ArticleDOI
Myocardial Infarction Mortality Risk After Treatment for Hodgkin Disease: A Collaborative British Cohort Study
Anthony J. Swerdlow,Craig D. Higgins,Paul Smith,David Cunningham,Barry W. Hancock,Alan Horwich,Peter Hoskin,Andrew Lister,John Radford,Ama Z. S. Rohatiner,David C. Linch +10 more
TL;DR: The risk of death from myocardial infarction after treatment for Hodgkin disease remains high for at least 25 years, and is related to supradiaphragmatic radiotherapy but may also be related to anthracycline and vincristine treatment.